Acelyrin Gains as Trium Capital Rebuffs M&A Deal With Alumis
Alumis Raises Share Consideration for Acelyrin Acquisition
Express News | Alumis Inc - Expects Runway to Fund Operations Into 2027
Express News | Alumis Inc - ACELYRIN Stockholders to Receive 0.4814 Shares of Alumis per Share
Press Release: Alumis and ACELYRIN Announce Amended Merger Agreement
Express News | Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
Insider Stock Sales Shake Up ACELYRIN, INC.
Insider Sale: Chief Executive Officer of $SLRN Sells 17,986 Shares
Acelyrin | 10-K: FY2024 Annual Report
Acelyrin Adopts Poison Pill as Tang Capital Partners Builds Stake
Acelyrin Adopts Stockholder Rights Plan; Shares Up Pre-Bell
Express News | ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
Express News | ACELYRIN Shares Down 6.5% After Co Reiterates Merger With Alumis
Express News | Refile-Buzz-ACELYRIN Slides After Reiterating Merger With Alumis Amid Concentra's Buyout Offer
Acelyrin Falls as Acelyrin Reaffirms Deal Commitment
Acelyrin Says Concentra Indication Not Expected to Result in Superior Proposal
Acelyrin and Alumis: Combined Company to Benefit From Differentiated Late-Stage Portfolio of Therapies and Strong Balance Sheet
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Press Release: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Press Release: Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger